TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30364565
Drug: Cardiac resynchronisation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronisation therapy (CRT)
Study: 31302353
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment alone
Study: 15973773
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) by intermission intravenous pulse with prednisone
Study: 11841992
Drug: Intravenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GLP-1
Study: 27487253
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (30 mg twice daily)
Study: 27487253
Drug: TEG‐adjusted enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEG‐adjusted enoxaparin dosing (35 mg twice daily)
Study: 25527750
Drug: Polydextrose (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (21 g/d)
Study: 22649263
Drug: Soluble corn
Normalized name: soluble corn fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble corn fiber (SCF; 21 g/d)
Study: 18057215
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment in patients with CKD
Study: 18057215
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in patients with CKD
Study: 16688995
Drug: Shexiang Injection
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
DrugBank: Moschus berezovskii musk sac resin (DB14247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Injection (SI) plus conventional therapy
Study: 10750647
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m2 every 4 weeks) + Tamoxifen (30 mg bid)
Study: 2125857
Drug: Ritanserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (30 mg daily p.o.)
Study: 2125857
Drug: Orphenadrine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orphenadrine (150 mg daily p.o.)
Study: 31083802
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C
Study: 31083802
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C in cirrhotic patients
Study: 31083802
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C in non-cirrhotic patients
Study: 31083802
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C in patients without end-of-treatment response (EoTR)
Study: 26154029
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 0.2 g/L 2'FL
Study: 26154029
Drug: Formula with
Normalized name: Stress B Formula with C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula with 1.0 g/L 2'FL
Study: 26456812
Drug: Chemotherapy (primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (primary treatment for ovarian cancer)
Study: 18445839
Drug: Pharmacokinetically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetically guided FU dose adjustment (arm B)
Study: 18445839
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of fluorouracil (arm A)
Study: 8773160
Drug: Baseline oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline oral glucose tolerance test (GTT)
Study: 3883729
Drug: Propranolol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60 to 120 mg daily)
Study: 30165520
Drug: Lower LT4
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lower LT4 dose
Study: 30165520
Drug: Perceived higher
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived higher LT4 doses
Study: 27424010
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (2.4 g/day for 8 weeks)
Study: 24448120
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg/day
Study: 16481597
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg/day
Study: 9583547
Drug: Paravertebral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paravertebral administration of bupivacaine
Study: 9583547
Drug: Interpleural administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpleural administration of bupivacaine
Study: 2534170
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefotaxime during resection and another 1 g dose when the bladder catheter was removed
Study: 2534170
Drug: no additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: no additional cefotaxime dose when the bladder catheter was removed
Study: 22129569
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) cilostazol 200 mg × 1 tablet, once daily
Study: 22129569
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) cilostazol 100 mg × 2 tablets, BID
Study: 22129569
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) cilostazol 200 mg × 1 tablet, once daily (fed state)
Study: 22129569
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of SR and IR formulations for 8 consecutive days
Study: 19189982
Drug: Levobupivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 10 mg h(‐1) at 0.5% concentration with sufentanil 2.6 microg h(‐1)
Study: 19189982
Drug: Levobupivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 10 mg h(‐1) at 0.25% concentration with sufentanil 2.6 microg h(‐1)
Study: 19189982
Drug: Levobupivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 10 mg h(‐1) at 0.15% concentration with sufentanil 2.6 microg h(‐1)
Study: 8435884
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g four times per day)
Study: 2071268
Drug: Imidazole salicylate
Normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazole salicylate (750 mg t.i.d.)
Study: 2071268
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg t.i.d.)
Study: 28827188
Drug: Capecitabine-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine-containing treatment (ATX)
Study: 27956003
Drug: Anacetrapib 100
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 100 mg
Study: 12556405
Drug: BQ-123 (ET(A)
Normalized name: ethanol
DrugBank: BQ-123 (DB12054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BQ-123 (ET(A) receptor antagonist)
Study: 2383162
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g/d intravenously for 2 weeks
Study: 2383162
Drug: Ceftriaxone (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (after initial placebo treatment)
Study: 6454249
Drug: Dicloxacillin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin administration for 6 days per- and postoperatively
Study: 29258928
Drug: Combined intravenous‐inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous‐inhalation anesthesia
Study: 17486027
Drug: Activated device
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated device treatment for 10 minutes (PDE study)
Study: 17486027
Drug: Activated device
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated device treatment for 10 minutes (SS study)
Study: 8640706
Drug: Adjuvant Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Active Specific Immunotherapy (ASI) with 3 intradermal injections of 10^7 autologous irradiated tumor cells mixed with 10^7 Bacillus Calmette‐Guèrin
Study: 8640706
Drug: Adjuvant Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Active Specific Immunotherapy (ASI)
Study: 19158317
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg daily for 4 weeks)
Study: 11893233
Drug: Prolonged-release alfuzosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release alfuzosin 10mg once daily
Study: 7357232
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (conversation training programme)
Study: 7357232
Drug: Behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural treatment control
Study: 17605771
Drug: Multidisciplinary assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary assessment and treatment of multifactorial fall risk factors.
Study: 15646610
Drug: Oraqix anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraqix anesthetic gel
Study: 9724256
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg for 21 days
Study: 7831626
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (BA+CS)
Study: 6487494
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg)
Study: 31597460
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen (60/30 mg daily)
Study: 31597460
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban regimen (30/15 mg daily)
Study: 28240714
Drug: 3% glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% glycerol solution containing 26 ml·kg of water and 1 g·kg of glycerol
Study: 28240714
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group drinking 26 ml·kg of water
Study: 14515286
Drug: PCA (patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA (patient-controlled analgesia) with morphine
Study: 7705704
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4 (22.5 mg/m2 FUDR and 6.75 mg/m2 cisplatin)
Study: 2649463
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) 12 g/m2 applied within 6 weeks
Study: 17537771
Drug: CPAP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP titration night
Study: 21277706
Drug: Placebo (flavor-matched,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (flavor-matched, tobacco-free preparation)
Study: 17728549
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment approaches (laser photocoagulation, PDT, subretinal surgery, novel anti-angiogenic drugs)
Study: 7995624
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (to raise plasma insulin 100 microU/mL)
Study: 3294036
Drug: Slow-release terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release terbutaline (b.i.d. 0.25 mg/kg per day)
Study: 3294036
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline (5.31 mg/kg morning and 10.62 mg/kg evening)
Study: 22188590
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 100 μg twice daily (BD)
Study: 22188590
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 200 μg OD
Study: 22188590
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 μg BD
Study: 16208143
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (nutritional doses)
Study: 11712619
Drug: Amisulpride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (50 mg o.d.)
Study: 11712619
Drug: Sertraline (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50‐100 mg o.d.)
Study: 9446006
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium channel blockers (III, n = 17)
Study: 31132111
Drug: FOLFOX +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX + 2 g oral curcumin/d (CUFOX)
Study: 26818096
Drug: 15-mg mirtazapine
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg mirtazapine (n = 8)
Study: 18265647
Drug: OS‐1 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS‐1 (oral rehydration solution)
Study: 18265647
Drug: KN3B (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN3B (intravenous maintenance solution)
Study: 12960999
Drug: L-arginine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (200 mg/kg infused intravenously over 4 hours, 12 and 3 hours before PCI, and 500 mg over 10 minutes prior to stent implantation, followed by oral supplementation of 6 g/day for 14 days after PCI)
Study: 9689421
Drug: Pentaerithritol tetranitrate
Normalized name: pentaerithrityl tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerithritol tetranitrate (PETN) 240 mg/d
Study: 9689421
Drug: Pentaerithritol tetranitrate
Normalized name: pentaerithrityl tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerithritol tetranitrate (PETN) 150 mg/d
Study: 7532087
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (6 million kallikrein inactivator units)
Study: 7532087
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (3 million kallikrein inactivator units)
Study: 7532087
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (3 million kallikrein inactivator units) with autologous blood transfusions
Study: 2673045
Drug: Sequential methotrexate-5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential methotrexate-5-fluorouracil (MF)
Study: 28497259
Drug: Intravenous valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproic acid (15 to 150 mg/kg)
Study: 27598804
Drug: Short-term androgen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen deprivation (STAD) combined with high-dose radiation therapy (HDRT)
Study: 18845605
Drug: Goal setting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants
Study: 16117862
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of bone‐marrow cells (BMCs)
Study: 11057001
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of orthographic and phonological cues
Study: 8853729
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg beta-carotene orally three times daily and multivitamins
Study: 6391665
Drug: Stuart Prenatal
Normalized name: Stuart Prenatal + DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stuart Prenatal tablets
Study: 29270622
Drug: External Vibration
Normalized name: VIBRATING DEVICE,CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Vibration Therapy (EVT)
Study: 25901558
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT (LDCT)
Study: 7726440
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (2.4 +/- 0.7 mg.kg‐1.h‐1)
Study: 7726440
Drug: Single nonsedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nonsedating bolus dose propofol (0.4 mg/kg)
Study: 1768821
Drug: Various strategies
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various strategies to manage cardiopulmonary bypass (hypothermia vs normothermia, presence vs absence of arterial microfilters, presence vs absence of glucose-containing solution in pump prime)
Study: 3138303
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily)
Study: 12940397
Drug: Hypnotic Stress
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic Stress Inoculation Training
Study: 12940397
Drug: Hypnotic analgesia
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic analgesia suggestions
Study: 12940397
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction treatment
Study: 3803414
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil (Isoptin) b.d. or t.d.s. (240, 360 or 480 mg daily)
Study: 24495617
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) co-administration
Study: 24495617
Drug: Screening using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening using urine steroid and LH measurements
Study: 23210198
Drug: Conventional orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional orthodontic therapy
Study: 20671206
Drug: Individualized oral
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized oral hygiene instruction (OHI)
Study: 20671206
Drug: OHI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI and annual applications of 38% silver diamine fluoride (SDF) solution
Study: 18701006
Drug: Sublingual specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual specific immunotherapy (SLIT), treated daily for at least two consecutive years.
Study: 8232945
Drug: Gabapentin (600,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600, 1,200, or 1,800 mg/d)
Study: 27103371
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion for 4h
Study: 27103371
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normoglycemia and GLP-1 for 4h
Study: 27103371
Drug: Hyperglycemia plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia plus GLP-1 infusion for 4h
Study: 25579357
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% eye drops once daily for 4 weeks
Study: 19996339
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 56 days
Study: 19996339
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 28 days (control group)
Study: 22170727
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/d
Study: 12088975
Drug: Tropisetron 2
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 2 mg IV
Study: 10218187
Drug: Therapy dog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy dog
Study: 2669441
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg clomipramine
Study: 1095963
Drug: Fructose-1-6-diphosphate sodium
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose-1-6-diphosphate sodium salt intravenously administered for 20 days at two daily doses of 2.5 mg
Study: 28679495
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing 80 μg sF with 2.5 μg GLA in SE
Study: 28408121
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (IIV)
Study: 3044425
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg
Study: 6689676
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg
Study: 26813677
Drug: G.H.3. tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: G.H.3. tablets
Study: 23083925
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg) administered at peak exercise during session #2